# Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

> **NCT00499031** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 38 (actual)

## Conditions studied

- Cervical Squamous Cell Carcinoma
- Recurrent Cervical Carcinoma

## Interventions

- **BIOLOGICAL:** Cetuximab

## Key facts

- **NCT ID:** NCT00499031
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2012-01
- **Final completion:** —
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499031, "Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00499031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*